BioCentury | Oct 3, 2020
Politics, Policy & Law

Congressional Democrats rehearse drug pricing attacks

Leaders of some of the world’s leading biopharma companies faced off last week against congressional Democrats – and were soundly defeated. The two-day hearing on drug pricing convened by the House Oversight...
BioCentury | Oct 1, 2020
Politics, Policy & Law

House committee targets Mallinckrodt, Amgen and Novartis over price increases

During the second and final day of a drug pricing hearing, Democratic members of the House Oversight and Reform Committee again pounded pharma CEOs, accusing them of taking unjustified price increases...
BioCentury | Oct 1, 2020
Politics, Policy & Law

Revlimid, Copaxone are poster children for price abuses, House committee says

The House Committee on Oversight and Reform Wednesday released reports and documents that, according to committee Democrats, demonstrate that drug companies take unjustified price increases and engage...
BioCentury | Aug 8, 2020
Translation in Brief

Cocrystal’s COVID-19 antivirals; plus a portable breast cancer diagnostic, Tarveda mini-drug conjugate for solid tumors, and more

...Brain-penetrant compound for autistic behaviors University of Basel researchers reported in Nature a brain penetrant MKNK1/2...
...in the ventral tegmental area, a brain region that contributes to the behavioral responses. The MKNK1/2...
...Epidermal growth factor receptor 2 Hsp90 - Heat shock protein 90 MKNK1 (MNK1) - MAP kinase interacting serine-threonine kinase 1...
BioCentury | Aug 7, 2020
Finance

Aug. 6 Quick Takes: More pressure on China’s U.S. listings; busy Editas; Athenex bestows royalty on Sagard; Longwood, CFF launch incubator and more

Trump admin plan would pressure U.S.-listed Chinese companies A Trump administration working group plan has recommended that Chinese companies listed on a U.S. stock exchange provide the Public Company Accounting Oversight Board with access to...
BioCentury | Jan 9, 2020
Company News

Pfizer dips into translational regulation for cancer with eFFECTOR deal

...has two programs in clinical development targeting the other components of the translation initiation complex: MKNK1/MKNK2...
...factor 4E eIF4A1 (EIF4A) - Eukaryotic translation initiation factor 4A K-Ras (KRAS) MKNK1 (MNK1) - MAP kinase interacting serine-threonine kinase 1...
BioCentury | Nov 26, 2019
Company News

After mid-decade makeover, Medicines Co. accepts Novartis' $9.7B bid on eve of inclisiran submission

Novartis’ $9.7 billion acquisition of The Medicines Co. gives the pharma an RNAi-based cholesterol-lowering therapy that could capture a larger share of the cardiovascular disease market than approved PCSK9 inhibitors have been able to grab....
BioCentury | Sep 28, 2019
Company News

Management tracks: Bourla to succeed Read as Pfizer chair; plus Phathom, OnKure, Forma, Beam, Noven, Cerebral, Alpha Tau and InsightRX

Ian Read will retire as chairman of Pfizer Inc. (NYSE:PFE) on Dec. 31, with CEO Albert Bourla his successor. Read has been with the pharma since 1978, becoming CEO in 2010 and chairman in 2011....
BioCentury | Sep 13, 2019
Politics, Policy & Law

Another chance to renew the social contract

The Business Roundtable, a club of CEOs of many of the largest U.S. corporations, has given biopharma companies a new impetus for telling the public how they plan to live up to their social commitments....
BioCentury | Sep 5, 2019
Company News

Sept. 5 Company Quick Takes: Zafgen exploring alternatives; plus BridgeBio, Global Blood, Akouos, Mallinckrodt, uBiome

Zafgen evaluating strategic options Metabolic company Zafgen Inc. (NASDAQ:ZFGN) has retained advisory firm MTS Health Partners to explore strategic alternatives after receiving new preclinical data that the company believes will be insufficient for FDA to...
Items per page:
1 - 10 of 143